Alexion Pharmaceuticals (ALXN) : Traders are bullish on Alexion Pharmaceuticals (ALXN) as it has outperformed the S&P 500 by a wide margin of 7.53% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 6.16%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 6.62% in the last 1 week, and is up 10.2% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Alexion Pharmaceuticals (NASDAQ:ALXN): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $135.84 and $135.43 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $138.26. The buying momentum continued till the end and the stock did not give up its gains. It closed at $137.11, notching a gain of 1.24% for the day. The total traded volume was 1,470,223 . The stock had closed at $135.43 on the previous day.
The stock has recorded a 20-day Moving Average of 7.03% and the 50-Day Moving Average is 5.12%. Alexion Pharmaceuticals, Inc. has dropped 2.75% during the last 3-month period . Year-to-Date the stock performance stands at -28.12%.
Alexion Pharmaceuticals (ALXN) : The most positive equity analysts on Alexion Pharmaceuticals (ALXN) expects the shares to touch $221, whereas, the least positive believes that the stock will trade at $140 in the short term. The company is covered by 15 Wall Street Brokerage Firms. The average price target for shares are $186.33 with an expected fluctuation of $25.93 from the mean.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.